Home - Calico
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program
News & Media - Calico
Welcome to the Calico media center. Please find below features on our R&D efforts as well as our official press releases. For media inquiries, please email press@calicolabs.com.
Collaborator Profiles - Calico
Calico and AbbVie’s Fosigotifator Selected for FDA’s New START Pilot Program Since 2015, Calico and the Broad Institute of MIT and Harvard have partnered to investigate the biology and genetics of aging and pursue early-stage drug discovery.
Calico Stories - Calico
Cardiometabolic diseases are an increasing global health burden. And Calico scientists, led by Madeleine Cule, are working with the University of Westminster and … Keep Reading
Susan Uptain, Ph.D. - Calico
In her role as Head of Project Team Leadership and Regulatory, Susan provides oversight and direction for Calico’s drug discovery and development programs as they transition from candidate nomination through IND filing and clinical proof of concept.
Michael Lenardo, M.D. - Calico
Mike joined Calico in 2024 as Chief Scientific Officer, a role in which he is responsible for the company’s overall research strategy. He is establishing a lab that will address the aging process and associated diseases, expanding upon his work in human genetics.
Patients - Calico
Calico registers interventional clinical trials conducted in patients on www.clinicaltrials.gov. If you are a patient interested in one of our clinical trials, please visit www.clinicaltrials.gov to learn more.
Partnering - Calico
Partnering with Calico provides people, resources, and capabilities to advance a full range of biotechnology R&D opportunities. Calico Stories May 24, 2024
John Whiting - Calico
John brings deep experience in the life sciences industry to leading Calico’s Finance functions. About As Chief Financial Officer, John is responsible for accounting and accounting operations, financial planning and analysis, facilities and lab operations, IT, communications, and …
Clinical Trial: Vanishing White Matter - Calico
Calico and AbbVie are currently conducting a Phase 1b/2 trial of fosigotifator to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of fosigotifator in participants diagnosed with VWM disease.